FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281877807> ?p ?o ?g. }

• W4281877807 endingPage "73" @default.
• W4281877807 startingPage "49" @default.
• W4281877807 abstract "As an anti–inflammatory strategy, MAPK–activated protein kinase–2 (MK2) inhibition can potentially avoid the clinical failures seen for direct p38 inhibitors, especially tachyphylaxis. CC-99677, a selective targeted covalent MK2 inhibitor, employs a rare chloropyrimidine that bonds to the sulfur of cysteine 140 in the ATP binding site via a nucleophilic aromatic substitutions (SNAr) mechanism. This irreversible mechanism translates biochemical potency to cells shown by potent inhibition of heat shock protein 27 (HSP27) phosphorylation in LPS-activated monocytic THP-1 cells. The cytokine inhibitory profile of CC-99677 differentiates it from known p38 inhibitors, potentially suppressing a p38 pathway inflammatory response while avoiding tachyphylaxis. Dosed orally, CC-99677 is efficacious in a rat model of ankylosing spondylitis. Single doses, 3 to 400 mg, in healthy human volunteers show linear pharmacokinetics and apparent sustained tumor necrosis factor-α inhibition, with a favorable safety profile. These results support further development of CC-99677 for autoimmune diseases like ankylosing spondylitis. As an anti–inflammatory strategy, MAPK–activated protein kinase–2 (MK2) inhibition can potentially avoid the clinical failures seen for direct p38 inhibitors, especially tachyphylaxis. CC-99677, a selective targeted covalent MK2 inhibitor, employs a rare chloropyrimidine that bonds to the sulfur of cysteine 140 in the ATP binding site via a nucleophilic aromatic substitutions (SNAr) mechanism. This irreversible mechanism translates biochemical potency to cells shown by potent inhibition of heat shock protein 27 (HSP27) phosphorylation in LPS-activated monocytic THP-1 cells. The cytokine inhibitory profile of CC-99677 differentiates it from known p38 inhibitors, potentially suppressing a p38 pathway inflammatory response while avoiding tachyphylaxis. Dosed orally, CC-99677 is efficacious in a rat model of ankylosing spondylitis. Single doses, 3 to 400 mg, in healthy human volunteers show linear pharmacokinetics and apparent sustained tumor necrosis factor-α inhibition, with a favorable safety profile. These results support further development of CC-99677 for autoimmune diseases like ankylosing spondylitis. At A Glance CommentaryMalona J, et al.BackgroundNumerous direct inhibitors of p38 kinase have been developed for inflammatory disorders, but these have repeatedly failed. Targeting other network members, like the MAPK-activated protein kinase-2 (MK2) downstream of p38, might allow for the sustained suppression of cytokine production required for therapeutic benefit. However, no MK2 inhibitors have been clinically approved to date.Translational SignificanceWe have discovered and characterized a potent, selective, covalent MK2 inhibitor, CC-99677. Orally-administered CC-99677 demonstrated efficacy in a rat model of ankylosing spondylitis and showed favorable safety in healthy human subjects. Cytokine blockade by CC-99677 may provide a potential therapy for cytokine-mediated, inflammatory disorders." @default.
• W4281877807 created "2022-06-13" @default.
• W4281877807 creator A5004177626 @default.
• W4281877807 creator A5007719190 @default.
• W4281877807 creator A5011157468 @default.
• W4281877807 creator A5025589384 @default.
• W4281877807 creator A5027996162 @default.
• W4281877807 creator A5034150242 @default.
• W4281877807 creator A5034487273 @default.
• W4281877807 creator A5034621627 @default.
• W4281877807 creator A5034685558 @default.
• W4281877807 creator A5044841282 @default.
• W4281877807 creator A5047548530 @default.
• W4281877807 creator A5049108938 @default.
• W4281877807 creator A5056257817 @default.
• W4281877807 creator A5060185042 @default.
• W4281877807 creator A5067040049 @default.
• W4281877807 creator A5074587441 @default.
• W4281877807 creator A5078965145 @default.
• W4281877807 creator A5084625519 @default.
• W4281877807 creator A5085456274 @default.
• W4281877807 creator A5089666769 @default.
• W4281877807 creator A5090303971 @default.
• W4281877807 date "2022-11-01" @default.
• W4281877807 modified "2023-10-10" @default.
• W4281877807 title "Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders" @default.
• W4281877807 cites W1555014582 @default.
• W4281877807 cites W1569578194 @default.
• W4281877807 cites W1587498640 @default.
• W4281877807 cites W1597420564 @default.
• W4281877807 cites W1977683934 @default.
• W4281877807 cites W1989331708 @default.
• W4281877807 cites W1995620440 @default.
• W4281877807 cites W2010993054 @default.
• W4281877807 cites W2012636104 @default.
• W4281877807 cites W2023771057 @default.
• W4281877807 cites W2026309161 @default.
• W4281877807 cites W2032154463 @default.
• W4281877807 cites W2032731042 @default.
• W4281877807 cites W2036039462 @default.
• W4281877807 cites W2037117792 @default.
• W4281877807 cites W2042450501 @default.
• W4281877807 cites W2044959738 @default.
• W4281877807 cites W2045074917 @default.
• W4281877807 cites W2046872014 @default.
• W4281877807 cites W2049560243 @default.
• W4281877807 cites W2063701247 @default.
• W4281877807 cites W2077554968 @default.
• W4281877807 cites W2081939329 @default.
• W4281877807 cites W2089203162 @default.
• W4281877807 cites W2105172098 @default.
• W4281877807 cites W2108921801 @default.
• W4281877807 cites W2109971160 @default.
• W4281877807 cites W2110808180 @default.
• W4281877807 cites W2117022661 @default.
• W4281877807 cites W2124026197 @default.
• W4281877807 cites W2124551692 @default.
• W4281877807 cites W2127551467 @default.
• W4281877807 cites W2146510390 @default.
• W4281877807 cites W2147949826 @default.
• W4281877807 cites W2152265294 @default.
• W4281877807 cites W2155905959 @default.
• W4281877807 cites W2157068896 @default.
• W4281877807 cites W2159211495 @default.
• W4281877807 cites W2161707506 @default.
• W4281877807 cites W2161975618 @default.
• W4281877807 cites W2169099584 @default.
• W4281877807 cites W2193377424 @default.
• W4281877807 cites W2278932593 @default.
• W4281877807 cites W2321662910 @default.
• W4281877807 cites W2325051172 @default.
• W4281877807 cites W2342992511 @default.
• W4281877807 cites W2525873843 @default.
• W4281877807 cites W2554626374 @default.
• W4281877807 cites W2743302399 @default.
• W4281877807 cites W2760718433 @default.
• W4281877807 cites W2765322245 @default.
• W4281877807 cites W2770303963 @default.
• W4281877807 cites W2770642598 @default.
• W4281877807 cites W2789800940 @default.
• W4281877807 cites W2799978617 @default.
• W4281877807 cites W2888979610 @default.
• W4281877807 cites W2899484277 @default.
• W4281877807 cites W2904506792 @default.
• W4281877807 cites W3200699517 @default.
• W4281877807 doi "https://doi.org/10.1016/j.trsl.2022.06.005" @default.
• W4281877807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35691544" @default.
• W4281877807 hasPublicationYear "2022" @default.
• W4281877807 type Work @default.
• W4281877807 citedByCount "6" @default.
• W4281877807 countsByYear W42818778072022 @default.
• W4281877807 countsByYear W42818778072023 @default.
• W4281877807 crossrefType "journal-article" @default.
• W4281877807 hasAuthorship W4281877807A5004177626 @default.
• W4281877807 hasAuthorship W4281877807A5007719190 @default.
• W4281877807 hasAuthorship W4281877807A5011157468 @default.
• W4281877807 hasAuthorship W4281877807A5025589384 @default.
• W4281877807 hasAuthorship W4281877807A5027996162 @default.

• next